<DOC>
	<DOC>NCT01500772</DOC>
	<brief_summary>This study is to evaluate the overall efficacy, and safety profile of the triple combination therapy of alisporivir (ALV; DEB025) plus peginterferon alfa-2a (PEG) and ribavirin (RBV) patients with chronic hepatitis C (HCV) genotype 1 who failed prior treatment with a protease inhibitor (PI).</brief_summary>
	<brief_title>Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>Inclusion criteria: 1. Patients with chronic HCV genotype 1 infection with previous PI treatment failure 2. Three months minimum time from the last dose of previous PI treatment to the first dose of study medication Exclusion criteria: 1. Use of other investigational drugs at the time of enrollment 2. History of hypersensitivity to PEG or RBV 3. Any null nonresponders to prior PEG/RBV treatment Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>PI treatment failure</keyword>
</DOC>